Siglec 9 for the diagnosis of ARDS

Siglec 9 用于诊断 ARDS

• 批准号: 9810521
• 负责人: Sajid Shahul
• 金额: $ 12.15万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-04 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9810521
• 关键词: Acute; Acute respiratory failure; Address; Admission activity; Adult Respiratory Distress Syndrome; Aldosterone Antagonists; Aspirin; Attenuated; Basic Science; Binding Proteins; Biological Markers; Blood; Catheters; Chest; Clinical; Clinical Research; Congestive Heart Failure; Data; Development; Diagnosis; Diagnostic; Disease; EFRAC; Early Diagnosis; Early Intervention; Endothelium; Epithelial; Goals; Heart failure; Heterogeneity; Hospital Mortality; Incidence; Induction of neuromuscular blockade; Inflammation; Inflammatory; Injury; Intensive Care Units; Lead; Leukocytes; Ligand Binding; Liquid substance; Lung; Lung Inflammation; Neutrophil Activation; Neutrophil Infiltration; Outcome; Patient-Focused Outcomes; Patients; Permeability; Pharmacologic Substance; Plasma; Prone Position; Pulmonary Edema; Randomized Controlled Trials; Risk; Risk stratification; Sample Size; Sampling; Serum; Severities; Sialic Acids; Source; Spironolactone; Surface; Testing; Uncertainty; Validation; Ventilator-induced lung injury; Work; base; clinical practice; cohort; effective therapy; experimental study; heart function; heart preservation; immune activation; improved; injury prevention; lung injury; mortality; mortality risk; mouse model; neutrophil; new therapeutic target; non cardiogenic pulmonary edema; outcome forecast; predictive tools; preservation; prognostic; randomized trial; receptor function; sialic acid binding Ig-like lectin; treatment trial; validation studies

Project Summary/Abstract Acute respiratory distress syndrome (ARDS) accounts for 10% of admissions and 30% of mortality in intensive care units. Despite extensive basic and clinical research, hospital mortality for patients with ARDS remains as high as 45%. Major reasons for the lack of effective therapies include the lack of tools for predicting which patients will develop ARDS and the difficulty of differentiating ARDS from other causes of pulmonary edema like congestive heart failure (CHF). Because of such diagnostic uncertainty, fewer than half of ARDS cases are recognized, and ARDS-specific therapies are underutilized by 25% worldwide. Using plasma samples from the Fluid and Catheter Treatment Trial (a randomized controlled trial of liberal versus conservative fluid management) in patients with ARDS, and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial (a randomized trial of spironolactone in patients with heart failure with preserved ejection fraction), we will in AIM 1 determine how well serum Siglec-9 distinguishes between ARDS and CHF and in AIM 2 Correlate Siglec-9 levels with ARDS severity and clinical outcomes. The results of this work have tremendous potential to enable earlier diagnosis, treatment, and prognostic assessment of patients with ARDS.

项目总结/摘要 急性呼吸窘迫综合征（ARDS）占重症监护病房的10%和30%的死亡率。 护理单位。尽管进行了广泛的基础和临床研究，但ARDS患者的住院死亡率仍然是 高达45%。缺乏有效治疗的主要原因包括缺乏预测哪些疾病的工具。 患者将发展为ARDS，并且难以将ARDS与其他原因的肺水肿区分开， 比如充血性心力衰竭由于这种诊断的不确定性，只有不到一半的ARDS病例 全球范围内，ARDS特异性治疗的利用率不足25%。使用血浆样本从 液体和导管治疗试验（自由与保守液体的随机对照试验 急性呼吸窘迫综合征（ARDS）患者的治疗，以及心功能保留性心力衰竭的治疗 醛固酮拮抗剂试验（螺内酯在心力衰竭患者中的随机试验， 射血分数），我们将在AIM 1中确定血清Siglec-9在ARDS和CHF之间的区分程度 在AIM 2中，将Siglec-9水平与ARDS严重程度和临床结局相关联。这项工作的结果有 这对于ARDS患者的早期诊断、治疗和预后评估具有巨大的潜力。